{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:32:34Z","timestamp":1791977554729,"version":"4.4.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82201445"],"award-info":[{"award-number":["No. 82201445"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82171309"],"award-info":[{"award-number":["No. 82171309"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-025-01984-7","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T09:41:32Z","timestamp":1741599692000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The efficacy and safety of zavegepant nasal inhalation versus oral calcitonin-gene related peptide receptor antagonists in the acute treatment of migraine: a systematic review and network meta-analysis of the literature"],"prefix":"10.1186","volume":"26","author":[{"given":"Zixiang","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyu","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meirong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"1984_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41572-021-00328-4","volume":"8","author":"MD Ferrari","year":"2022","unstructured":"Ferrari MD et al (2022) Migraine. Nat Rev Dis Primers 8:2. https:\/\/doi.org\/10.1038\/s41572-021-00328-4","journal-title":"Nat Rev Dis Primers"},{"key":"1984_CR2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/s0140-6736(04)15440-8","volume":"363","author":"SD Silberstein","year":"2004","unstructured":"Silberstein SD (2004) Migraine. Lancet 363:381\u2013391. https:\/\/doi.org\/10.1016\/s0140-6736(04)15440-8","journal-title":"Lancet"},{"key":"1984_CR3","doi-asserted-by":"publisher","unstructured":"GBD 2016 Neurology Collaborators (2019) Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 18:459\u2013480. https:\/\/doi.org\/10.1016\/s1474-4422(18)30499-x","DOI":"10.1016\/s1474-4422(18)30499-x"},{"key":"1984_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ et al (2020) Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21:137. https:\/\/doi.org\/10.1186\/s10194-020-01208-0","journal-title":"J Headache Pain"},{"key":"1984_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1526-4610.2011.02046.x","volume":"52","author":"D Buse","year":"2012","unstructured":"Buse D et al (2012) Headache impact of chronic and episodic migraine: results from the American migraine prevalence and prevention study. Headache 52:3\u201317. https:\/\/doi.org\/10.1111\/j.1526-4610.2011.02046.x","journal-title":"Headache"},{"key":"1984_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s10194-019-0993-0","volume":"20","author":"M Leonardi","year":"2019","unstructured":"Leonardi M, Raggi A (2019) A narrative review on the burden of migraine: when the burden is the impact on people\u2019s life. J Headache Pain 20:41. https:\/\/doi.org\/10.1186\/s10194-019-0993-0","journal-title":"J Headache Pain"},{"key":"1984_CR7","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/s0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M et al (2021) Migraine: epidemiology and systems of care. Lancet 397:1485\u20131495. https:\/\/doi.org\/10.1016\/s0140-6736(20)32160-7","journal-title":"Lancet"},{"issue":"Suppl 4","key":"1984_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/head.12601","volume":"55","author":"C Cameron","year":"2015","unstructured":"Cameron C et al (2015) Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache 55(Suppl 4):221\u2013235. https:\/\/doi.org\/10.1111\/head.12601","journal-title":"Headache"},{"key":"1984_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.28544","volume":"4","author":"CP Yang","year":"2021","unstructured":"Yang CP et al (2021) Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open 4:e2128544. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.28544","journal-title":"JAMA Netw Open"},{"key":"1984_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118702","volume":"571","author":"A Chokshi","year":"2019","unstructured":"Chokshi A et al (2019) Intranasal spray formulation containing rizatriptan benzoate for the treatment of migraine. Int J Pharm 571:118702. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.118702","journal-title":"Int J Pharm"},{"key":"1984_CR11","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1001\/jama.2021.7939","volume":"325","author":"JH VanderPluym","year":"2021","unstructured":"VanderPluym JH et al (2021) Acute treatments for episodic migraine in adults: a systematic review and meta-analysis. JAMA 325:2357\u20132369. https:\/\/doi.org\/10.1001\/jama.2021.7939","journal-title":"JAMA"},{"key":"1984_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107528","volume":"211","author":"T de Vries","year":"2020","unstructured":"de Vries T, Villal\u00f3n CM, MaassenVanDenBrink A (2020) Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther 211:107528. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107528","journal-title":"Pharmacol Ther"},{"key":"1984_CR13","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1161\/circresaha.123.321673","volume":"132","author":"L B\u00e1lint","year":"2023","unstructured":"B\u00e1lint L et al (2023) Clinical potential of adrenomedullin signaling in the cardiovascular system. Circ Res 132:1185\u20131202. https:\/\/doi.org\/10.1161\/circresaha.123.321673","journal-title":"Circ Res"},{"key":"1984_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-021-01279-7","volume":"22","author":"M Ashina","year":"2021","unstructured":"Ashina M et al (2021) Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study. J Headache Pain 22:68. https:\/\/doi.org\/10.1186\/s10194-021-01279-7","journal-title":"J Headache Pain"},{"key":"1984_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s10194-021-01376-7","volume":"23","author":"P McAllister","year":"2022","unstructured":"McAllister P et al (2022) Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study. J Headache Pain 23:22. https:\/\/doi.org\/10.1186\/s10194-021-01376-7","journal-title":"J Headache Pain"},{"key":"1984_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s10194-021-01351-2","volume":"22","author":"SJ Nahas","year":"2021","unstructured":"Nahas SJ et al (2021) Efficacy and safety of fremanezumab in clinical trial participants aged \u226560 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies. J Headache Pain 22:141. https:\/\/doi.org\/10.1186\/s10194-021-01351-2","journal-title":"J Headache Pain"},{"key":"1984_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2020.127624","volume":"31","author":"SE Mercer","year":"2021","unstructured":"Mercer SE et al (2021) Azepino-indazoles as calcitonin gene-related peptide (CGRP) receptor antagonists. Bioorg Med Chem Lett 31:127624. https:\/\/doi.org\/10.1016\/j.bmcl.2020.127624","journal-title":"Bioorg Med Chem Lett"},{"key":"1984_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241259456","volume":"44","author":"K Mullin","year":"2024","unstructured":"Mullin K et al (2024) Long-term safety of zavegepant nasal spray for the acute treatment of migraine: a phase 2\/3 open-label study. Cephalalgia 44:3331024241259456. https:\/\/doi.org\/10.1177\/03331024241259456","journal-title":"Cephalalgia"},{"key":"1984_CR19","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1080\/14737175.2024.2405741","volume":"24","author":"G Greco","year":"2024","unstructured":"Greco G, Monteith T (2024) Intranasal zavegepant for the acute treatment of migraine. Expert Rev Neurother 24:1131\u20131140. https:\/\/doi.org\/10.1080\/14737175.2024.2405741","journal-title":"Expert Rev Neurother"},{"key":"1984_CR20","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1177\/10600280231209439","volume":"58","author":"AL Martirosov","year":"2024","unstructured":"Martirosov AL et al (2024) Zavegepant intranasal spray for migraines. Ann Pharmacother 58:827\u2013833. https:\/\/doi.org\/10.1177\/10600280231209439","journal-title":"Ann Pharmacother"},{"key":"1984_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"1984_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/s1474-4422(22)00517-8","volume":"22","author":"RB Lipton","year":"2023","unstructured":"Lipton RB et al (2023) Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol 22:209\u2013217. https:\/\/doi.org\/10.1016\/s1474-4422(22)00517-8","journal-title":"Lancet Neurol"},{"key":"1984_CR23","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/head.14389","volume":"62","author":"R Croop","year":"2022","unstructured":"Croop R et al (2022) Zavegepant nasal spray for the acute treatment of migraine: a phase 2\/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache 62:1153\u20131163. https:\/\/doi.org\/10.1111\/head.14389","journal-title":"Headache"},{"key":"1984_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s10194-022-01463-3","volume":"23","author":"R Cady","year":"2022","unstructured":"Cady R et al (2022) Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study. J Headache Pain 23:91. https:\/\/doi.org\/10.1186\/s10194-022-01463-3","journal-title":"J Headache Pain"},{"key":"1984_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40120-021-00234-7","volume":"10","author":"S Hutchinson","year":"2021","unstructured":"Hutchinson S et al (2021) Ubrogepant for the acute treatment of migraine: pooled efficacy, safety, and tolerability from the ACHIEVE I and ACHIEVE II phase 3 randomized trials. Neurol Ther 10:235\u2013249. https:\/\/doi.org\/10.1007\/s40120-021-00234-7","journal-title":"Neurol Ther"},{"key":"1984_CR26","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","volume":"381","author":"DW Dodick","year":"2019","unstructured":"Dodick DW et al (2019) Ubrogepant for the treatment of migraine. N Engl J Med 381:2230\u20132241. https:\/\/doi.org\/10.1056\/NEJMoa1813049","journal-title":"N Engl J Med"},{"key":"1984_CR27","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.2019.16711","volume":"322","author":"RB Lipton","year":"2019","unstructured":"Lipton RB et al (2019) Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA 322:1887\u20131898. https:\/\/doi.org\/10.1001\/jama.2019.16711","journal-title":"JAMA"},{"key":"1984_CR28","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/s0140-6736(19)31606-x","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R et al (2019) Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 394:737\u2013745. https:\/\/doi.org\/10.1016\/s0140-6736(19)31606-x","journal-title":"Lancet"},{"key":"1984_CR29","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB et al (2019) Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med 381:142\u2013149. https:\/\/doi.org\/10.1056\/NEJMoa1811090","journal-title":"N Engl J Med"},{"key":"1984_CR30","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1177\/0333102416653233","volume":"36","author":"T Voss","year":"2016","unstructured":"Voss T et al (2016) A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia 36:887\u2013898. https:\/\/doi.org\/10.1177\/0333102416653233","journal-title":"Cephalalgia"},{"key":"1984_CR31","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/0333102413500727","volume":"34","author":"R Marcus","year":"2014","unstructured":"Marcus R et al (2014) BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 34:114\u2013125. https:\/\/doi.org\/10.1177\/0333102413500727","journal-title":"Cephalalgia"},{"key":"1984_CR32","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1177\/0333102411398399","volume":"31","author":"DJ Hewitt","year":"2011","unstructured":"Hewitt DJ et al (2011) Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 31:712\u2013722. https:\/\/doi.org\/10.1177\/0333102411398399","journal-title":"Cephalalgia"},{"key":"1984_CR33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/0333102410388435","volume":"31","author":"HC Diener","year":"2011","unstructured":"Diener HC et al (2011) BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 31:573\u2013584. https:\/\/doi.org\/10.1177\/0333102410388435","journal-title":"Cephalalgia"},{"key":"1984_CR34","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1212\/WNL.0b013e3181b87942","volume":"73","author":"KM Connor","year":"2009","unstructured":"Connor KM et al (2009) Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 73:970\u2013977. https:\/\/doi.org\/10.1212\/WNL.0b013e3181b87942","journal-title":"Neurology"},{"key":"1984_CR35","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/s0140-6736(08)61626-8","volume":"372","author":"TW Ho","year":"2008","unstructured":"Ho TW et al (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372:2115\u20132123. https:\/\/doi.org\/10.1016\/s0140-6736(08)61626-8","journal-title":"Lancet"},{"key":"1984_CR36","doi-asserted-by":"publisher","unstructured":"Ho TW et al (2008) Randomized controlled trial of an oral CGRP receptor antagonist MK-0974 in acute treatment of migraine Neurology 70(16) 1304\u20131312. https:\/\/doi.org\/10.1212\/01.WNL.0000286940.29755.61","DOI":"10.1212\/01.WNL.0000286940.29755.61"},{"key":"1984_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou A et al (2020) CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med 17:e1003082. https:\/\/doi.org\/10.1371\/journal.pmed.1003082","journal-title":"PLoS Med"},{"key":"1984_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1080","volume":"16","author":"T Papakonstantinou","year":"2020","unstructured":"Papakonstantinou T et al (2020) CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis. Campbell Syst Rev 16:e1080. https:\/\/doi.org\/10.1002\/cl2.1080","journal-title":"Campbell Syst Rev"},{"key":"1984_CR39","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jclinepi.2021.09.014","volume":"141","author":"X Li","year":"2022","unstructured":"Li X et al (2022) Evidence based social science in China paper 3: the quality of social science RCTs published from 2000\u20132020. J Clin Epidemiol 141:64\u201373. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.09.014","journal-title":"J Clin Epidemiol"},{"key":"1984_CR40","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1177\/0333102419828967","volume":"39","author":"HC Diener","year":"2019","unstructured":"Diener HC et al (2019) Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia 39:687\u2013710. https:\/\/doi.org\/10.1177\/0333102419828967","journal-title":"Cephalalgia"},{"key":"1984_CR41","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1177\/0333102417736900","volume":"39","author":"L Edvinsson","year":"2019","unstructured":"Edvinsson L, Warfvinge K (2019) Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia 39:366\u2013373. https:\/\/doi.org\/10.1177\/0333102417736900","journal-title":"Cephalalgia"},{"key":"1984_CR42","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1152\/physrev.00059.2021","volume":"103","author":"AF Russo","year":"2023","unstructured":"Russo AF, Hay DL (2023) CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiol Rev 103:1565\u20131644. https:\/\/doi.org\/10.1152\/physrev.00059.2021","journal-title":"Physiol Rev"},{"key":"1984_CR43","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/s1474-4422(21)00409-9","volume":"21","author":"L Al-Hassany","year":"2022","unstructured":"Al-Hassany L et al (2022) Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. Lancet Neurol 21:284\u2013294. https:\/\/doi.org\/10.1016\/s1474-4422(21)00409-9","journal-title":"Lancet Neurol"},{"key":"1984_CR44","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s10194-024-01846-8","volume":"25","author":"DM Boucherie","year":"2024","unstructured":"Boucherie DM et al (2024) Comparison of gepant effects at therapeutic plasma concentrations: connecting pharmacodynamics and pharmacokinetics. J Headache Pain 25:141. https:\/\/doi.org\/10.1186\/s10194-024-01846-8","journal-title":"J Headache Pain"},{"key":"1984_CR45","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M (2020) Migraine. N Engl J Med 383:1866\u20131876. https:\/\/doi.org\/10.1056\/NEJMra1915327","journal-title":"N Engl J Med"},{"key":"1984_CR46","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1212\/con.0000000000001402","volume":"30","author":"R Burch","year":"2024","unstructured":"Burch R (2024) Acute treatment of migraine. Continuum (Minneap Minn) 30:344\u2013363. https:\/\/doi.org\/10.1212\/con.0000000000001402","journal-title":"Continuum (Minneap Minn)"},{"key":"1984_CR47","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1056\/NEJMra010917","volume":"346","author":"PJ Goadsby","year":"2002","unstructured":"Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine\u2013current understanding and treatment. N Engl J Med 346:257\u2013270. https:\/\/doi.org\/10.1056\/NEJMra010917","journal-title":"N Engl J Med"},{"key":"1984_CR48","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrneurol.2016.124","volume":"12","author":"HC Diener","year":"2016","unstructured":"Diener HC et al (2016) Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol 12:575\u2013583. https:\/\/doi.org\/10.1038\/nrneurol.2016.124","journal-title":"Nat Rev Neurol"},{"key":"1984_CR49","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1526-4610.2004.04078.x","volume":"44","author":"D Dodick","year":"2004","unstructured":"Dodick D et al (2004) Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 44:414\u2013425. https:\/\/doi.org\/10.1111\/j.1526-4610.2004.04078.x","journal-title":"Headache"},{"key":"1984_CR50","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s10194-023-01662-6","volume":"24","author":"G Li","year":"2023","unstructured":"Li G et al (2023) Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis. J Headache Pain 24:129. https:\/\/doi.org\/10.1186\/s10194-023-01662-6","journal-title":"J Headache Pain"},{"key":"1984_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.174902","volume":"922","author":"JBR Dos Santos","year":"2022","unstructured":"Dos Santos JBR, da Silva MRR (2022) Small molecule CGRP receptor antagonists for the preventive treatment of migraine: a review. Eur J Pharmacol 922:174902. https:\/\/doi.org\/10.1016\/j.ejphar.2022.174902","journal-title":"Eur J Pharmacol"},{"key":"1984_CR52","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40265-020-01300-4","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S (2020) Eptinezumab: first approval. Drugs 80:733\u2013739. https:\/\/doi.org\/10.1007\/s40265-020-01300-4","journal-title":"Drugs"},{"key":"1984_CR53","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41582-023-00803-4","volume":"19","author":"H Ashina","year":"2023","unstructured":"Ashina H, Tfelt-Hansen P (2023) Zavegepant for the acute treatment of migraine: look before leaping. Nat Rev Neurol 19:329\u2013330. https:\/\/doi.org\/10.1038\/s41582-023-00803-4","journal-title":"Nat Rev Neurol"},{"key":"1984_CR54","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/17512433.2017.1339600","volume":"10","author":"S Silberstein","year":"2017","unstructured":"Silberstein S (2017) AVP-825: a novel intranasal delivery system for low-dose sumatriptan powder in the treatment of acute migraine. Expert Rev Clin Pharmacol 10:821\u2013832. https:\/\/doi.org\/10.1080\/17512433.2017.1339600","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1984_CR55","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2165\/00003088-200241110-00002","volume":"41","author":"E Fuseau","year":"2002","unstructured":"Fuseau E et al (2002) Clinical pharmacokinetics of intranasal sumatriptan. Clin Pharmacokinet 41:801\u2013811. https:\/\/doi.org\/10.2165\/00003088-200241110-00002","journal-title":"Clin Pharmacokinet"},{"key":"1984_CR56","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40120-023-00556-8","volume":"13","author":"RB Lipton","year":"2024","unstructured":"Lipton RB et al (2024) Real-world use of ubrogepant as acute treatment for migraine with an anti-calcitonin gene-related peptide monoclonal antibody: results from COURAGE. Neurol Ther 13:69\u201383. https:\/\/doi.org\/10.1007\/s40120-023-00556-8","journal-title":"Neurol Ther"},{"key":"1984_CR57","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/s0928-0987(97)00073-0","volume":"6","author":"C Duquesnoy","year":"1998","unstructured":"Duquesnoy C et al (1998) Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur J Pharm Sci 6:99\u2013104. https:\/\/doi.org\/10.1016\/s0928-0987(97)00073-0","journal-title":"Eur J Pharm Sci"},{"key":"1984_CR58","doi-asserted-by":"publisher","unstructured":"Adams AM et al (2022) Real-world effectiveness of ubrogepant for the acute treatment of migraine when used in combination with an anti-calcitonin gene- related peptide monoclonal antibody preventive: results from the COURAGE study. Neurol Ther 13:69-83. https:\/\/doi.org\/10.1007\/s40120-023-00556-8","DOI":"10.1007\/s40120-023-00556-8"},{"issue":"Suppl 1","key":"1984_CR59","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/head.12110","volume":"53","author":"M Pierce","year":"2013","unstructured":"Pierce M (2013) Oral triptans and nausea: treatment considerations in migraine. Headache 53(Suppl 1):17\u201320. https:\/\/doi.org\/10.1111\/head.12110","journal-title":"Headache"},{"key":"1984_CR60","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/psp4.13140","volume":"13","author":"JH Hughes","year":"2024","unstructured":"Hughes JH et al (2024) Concentration-QTc and cardiac safety analysis of single and multiple zavegepant nasal spray doses in healthy participants to support approval. CPT Pharmacometrics Syst Pharmacol 13:1044\u20131054. https:\/\/doi.org\/10.1002\/psp4.13140","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1984_CR61","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10194-005-0220-z","volume":"6","author":"E Sternieri","year":"2005","unstructured":"Sternieri E et al (2005) Pharmacokinetics of sumatriptan in non-respondent and in adverse drug reaction reporting migraine patients. J Headache Pain 6:319\u2013321. https:\/\/doi.org\/10.1007\/s10194-005-0220-z","journal-title":"J Headache Pain"},{"key":"1984_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-024-01915-y","volume":"26","author":"L Powell","year":"2025","unstructured":"Powell L et al (2025) Reduction of pain and functional disability over time in patients treated with zavegepant: a post-hoc analysis of the BHV3500-301 phase 3 randomized controlled trial. J Headache Pain 26:1. https:\/\/doi.org\/10.1186\/s10194-024-01915-y","journal-title":"J Headache Pain"},{"key":"1984_CR63","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2165\/00003088-199631010-00005","volume":"31","author":"NG Schneider","year":"1996","unstructured":"Schneider NG et al (1996) Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems. Clin Pharmacokinet 31:65\u201380. https:\/\/doi.org\/10.2165\/00003088-199631010-00005","journal-title":"Clin Pharmacokinet"},{"key":"1984_CR64","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1007\/s10072-022-06184-8","volume":"43","author":"C Altamura","year":"2022","unstructured":"Altamura C et al (2022) Gepants - a long way to cure: a narrative review. Neurol Sci 43:5697\u20135708. https:\/\/doi.org\/10.1007\/s10072-022-06184-8","journal-title":"Neurol Sci"},{"key":"1984_CR65","doi-asserted-by":"publisher","DOI":"10.52965\/001c.35506","volume":"10","author":"N Noor","year":"2022","unstructured":"Noor N et al (2022) A comprehensive review of zavegepant as abortive treatment for migraine. Health Psychol Res 10:35506. https:\/\/doi.org\/10.52965\/001c.35506","journal-title":"Health Psychol Res"},{"key":"1984_CR66","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s10194-024-01723-4","volume":"25","author":"X Deng","year":"2024","unstructured":"Deng X et al (2024) Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials. J Headache Pain 25:16. https:\/\/doi.org\/10.1186\/s10194-024-01723-4","journal-title":"J Headache Pain"},{"key":"1984_CR67","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1526-4610.2006.00301.x","volume":"46","author":"PJ Goadsby","year":"2006","unstructured":"Goadsby PJ, Yates R (2006) Zolmitriptan intranasal: a review of the pharmacokinetics and clinical efficacy. Headache 46:138\u2013149. https:\/\/doi.org\/10.1111\/j.1526-4610.2006.00301.x","journal-title":"Headache"},{"key":"1984_CR68","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/head.14853","volume":"65","author":"R Bhardwaj","year":"2025","unstructured":"Bhardwaj R et al (2025) Assessment of pharmacokinetic and pharmacodynamic interactions between zavegepant and sumatriptan: a phase 1, randomized, placebo-controlled study in healthy adults. Headache 65:315\u2013325. https:\/\/doi.org\/10.1111\/head.14853","journal-title":"Headache"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-01984-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-01984-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-01984-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T09:41:36Z","timestamp":1741599696000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-01984-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1984"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-01984-7","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}